Provided by Tiger Fintech (Singapore) Pte. Ltd.

VYNE Therapeutics Inc.

0.3529
-0.0127-3.47%
Post-market: 0.35500.0021+0.60%19:58 EDT
Volume:2.96M
Turnover:1.05M
Market Cap:5.88M
PE:-0.36
High:0.3650
Open:0.3436
Low:0.3436
Close:0.3656
Loading ...

BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy

MT Newswires Live
·
31 Jul

VYNE Therapeutics downgraded to Neutral from Buy at BTIG

TIPRANKS
·
31 Jul

VYNE Therapeutics: Buy Rating Supported by Promising VYN202 Prospects Amidst Challenges

TIPRANKS
·
31 Jul

BUZZ-U.S. STOCKS ON THE MOVE-Electronic Arts, AEP, Peloton Interactive

Reuters
·
31 Jul

VYNE Therapeutics (VYNE) was downgraded to a Hold Rating at LifeSci Capital

TIPRANKS
·
30 Jul

VYNE Therapeutics downgraded at H.C. Wainwright after vitiligo trial miss

TIPRANKS
·
30 Jul

US Stocks Edge Higher; Kraft Heinz Earnings Top Views

Benzinga
·
30 Jul

BUZZ-Vyne halts skin disease drug trial after failure; shares plunge

Reuters
·
30 Jul

Vyne Therapeutics' Phase 2b Trial of Repibresib Gel in Nonsegmental Vitiligo Misses Primary Endpoint

MT Newswires Live
·
30 Jul

Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today?

TIPRANKS
·
30 Jul

VYNE Therapeutics Announces Topline Results from Phase 2b Trial of Repibresib Gel in Nonsegmental Vitiligo, Will Seek External Partner for Further Development

Reuters
·
30 Jul

Vyne Therapeutics Announces Topline Results From Phase 2B Trial With Repibresib Gel in Nonsegmental Vitiligo

THOMSON REUTERS
·
30 Jul

Vyne Therapeutics Inc - Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-Vasi50 and F-Vasi75

THOMSON REUTERS
·
30 Jul

Vyne Therapeutics Inc - Will Terminate Extension Phase of Trial and Seek External Partner for Continued Development of Repibresib

THOMSON REUTERS
·
30 Jul

Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study

TIPRANKS
·
09 Jul

VYNE Therapeutics’ VYN202: Regulatory Milestones and Promising Clinical Data Drive Buy Rating

TIPRANKS
·
03 Jul

BRIEF-Vyne Therapeutics Provides Program Update On Oral BET Inhibitor VYN202

Reuters
·
02 Jul

VYNE Therapeutics provides program update on VYN202 following clinical hold

TIPRANKS
·
02 Jul

VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating

TIPRANKS
·
09 May

Vyne Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May